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Autoimmunity and Novel Therapies in Immune-Mediated
Thrombocytopenia
Dana Yehudai,a Elias Toubi,b Yehuda Shoenfeld,c and Zahava VadaszbImmune-mediated thrombocytopenic purpura (ITP) is recognized as a cell-specific autoimmune0037-1963
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S100disorder, yet, multifactorial in origin. The development of thrombocytopenia is well proven to
be mediated by both humoral (anti-platelet antibodies) and cellular (T-cell) mediated
mechanisms. In some cases other autoantibodies are also induced, eg, antinuclear antibody
(ANA), anti-dsDNA, and anti-cardiolipin, in addition to anti-platelet antibodies. The persistance
of these autoantibodies during the course of ITP could herald future development of another
autoimmune disease, eg, systemic lupus erythematosus (SLE) or anti-phospholipid syndrome
(APS). Due to the better understanding of the pathophysiology of ITP, new novel therapies
were introduced aiming to achieve long-lasting remissions. In this review we will focus on the
autoimmune nature of the disease and on some of the mechanisms of action of these new
therapies.
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mmune thrombocytopenic purpura (ITP) is con-
sidered a classical autoimmune disorder charac-
terized as the occurrence of thrombocytopenia
(platelet counto 100  103/mL. Platelet destruc-
tion by the spleen and morphologic abnormalities
of megakaryocytes followed by their altered matura-
tion are suggested to be the main pathogenic
abnormalities in ITP. Later, ITP was well defined to
be the result of a plasma factor proven as specific
anti-platelet antibodies and finally defining ITP as an
autoimmune disorder.1–3 Recent literature accepts
the classification of three phases of ITP: (1) the new-
onset phase that occurs within 3 months from
diagnosis; (2) the persistent phase, lasting between
3 and 12 months from diagnosis; and (3) the chronic
phase, defined as lasting more than 12 months.4
Patients who are diagnosed with ITP who repeti-
tively bleed considered to have ‘‘severe’’ ITP andblished by Elsevier Inc.
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including splenectomy and other novel therapies
such as rituximab and syk inhibitors.5 Though many
reports have pointed to the notion that ITP is
predominantly a disorder of young women, some
have shown a progressive increase in incidence with
age. However, the demographics of ITP probably
depend on regional differences due to different
predisposing infections, and the early diagnosis or
the better treatments of B-cell neoplasms.6
When ITP is isolated and no evidence for systemic
diseases is proven, primary ITP is then defined;
primary ITP represents 80% of all cases. However,
secondary ITP is defined when various well-proven
infectious or autoimmune diseases are responsible
for the development of thrombocytopenia. These
include viral infections such as hepatitis C virus
(HCV), cytomegalovirus (CMV), and Helicobacter
pylori, and also cases of ITP that were recognized
as a result of vaccination.7,8 Many viral particles such
as HCV were described to polyclonally activate B
cells by binding CD81 (part of the B cell co-receptor)
or other receptors in the case of CMV, predisposing
to the expansion of autoreactive B cells, the produc-
tion of anti-viral antibodies that cross-react with
membrane platelet antigens. In some studies the
presence of multiple autoantibodies was docu-
mented and suggested to be the result of epitope
spreading.9,10 A wide spectrum of autoimmune dis-
eases such as systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), antiphospholipid syn-
drome (APS), and immune deficiencies like commongy, Vol 50, No 1, Suppl 1, January 2013, pp S100–S108
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list of diseases reported to be responsible for secon-
dary ITP. Chronic lymphocytic leukemia (CLL) and
various lymphomas are additional diseases in the list
of all the above, all of which do not exceed 20%.11–13THE DIVERSITY OF IMMUNE-MEDIATED
ABERRATIONS IN ITP
Early studies showed already that when isolated
platelets from ITP patients were incubated with
autologous lymphocytes, they induced their trans-
formation and resulted in increased interleukin (IL)-2
productions. The responsive cells were proven to be
CD4þ T cells and were shown to react specifically
against modified glycoprotein (GP)IIb-IIIa on acti-
vated platelets. In addition to CD4þ T-cell activation,
it was also noticed that the stimulation of ITP B cells
resulted in the in vitro production of anti-platelet
antibodies. However, the same stimulation of normal
B cells did not induce such autoantibodies. Of
interest is that the depletion of CD19þ B cells was
followed by a complete disappearance of these
antibodies. Using antigen-specific assays such as
immunoprecipitation, immunoblot, and antigen cap-
ture techniques, these autoantibodies were shown
to be highly specific, and to recognize antigens that
are derived from either a single or multiple glyco-
proteins. The most identified autoantibodies in ITP
are those against GPIIb-IIIa and/or GPIb-IX, but there
have also been reports of autoantibodies against
GPIa-IIa and GPIV.14,15 When assessed positively,
these autoantibodies are considered a diagnostic
hallmark of ITP with a sensitivity of 49%–66% and
a specificity of 78%–93%; however, negative results
do not rule out this diagnosis.16 The most likely
explanation for negative assays is that other mecha-
nisms are involved in the pathophysiology of ITP
that do not involve anti-platelet antibodies, such as
T-cell–dependent platelet destruction or inhibition
of platelet production.
The persistent destruction of platelets by macro-
phages induces the continuous processing and pre-
sentation of the above membrane glycoproteins by
antigen-presenting cells (APCs), which is a crucial
step for the generation of pathogenic anti-platelet
antibodies. Aiming to better understand this process,
GPIIb/GPIIIa-reactive T-cell lines generated from ITP
patients were cultured with autologous freshly iso-
lated splenic macrophages, B cells, or dendritic cells
(DCs). Macrophages induced the proliferation of
GPIIb/IIIa-reactive T-cell lines without an exogenous
antigen, but B cells and DCs required glycoprotein
peptides to stimulate the T cells. Cultured macro-
phages that captured opsonized platelets promoted
anti-GPIIb/GPIIIa antibody production in mixed cul-
tures of autologous GPIIb/GPIIIa-reactive T-cell linesand B cells. The T-cell response was inhibited by
anti-FcgRI antibody. Thus, splenic macrophages that
take up opsonized platelets via FcgRI are major APCs
for cryptic glycoprotein peptides, and are central to
the maintenance of anti-platelet autoantibody pro-
duction in ITP patients.17 In another study, it was
reported that macrophages activated by C-reactive
protein (CRP) transfer suppression of ITP. Suppres-
sion of ITP by CRP-treated splenocytes required
FcgRI on the donor cell and FcgRIIb in the recipient
mice. These findings suggest that CRP generates
suppressive macrophages through FcgRI, which
then act through an FcgRIIb-dependent pathway in
the recipient to decrease platelet clearance.18EFFECTOR VERSUS T-REGULATORY CELLS
IN ITP
The immune response to glycoproteins in ITP is
usually modulated by CD4þ effector cells and CD8þ
cytotoxic cells. In thymus, T cells lose either the
CD4 or CD8 antigens and are released as either
CD4þ effector or CD8þ cytotoxic T cells (CTLs).
Some self-reactive T cells survive thymic depletion,
and persist in peripheral blood as autoreactive and
mediate autoimmunity. Normally, autoreactive T
cells are controlled by many peripheral self-
tolerance mechanisms such as altered co-
stimulatory molecules and or failure of T-regulatory
cell (Treg) function. When self-tolerance fails, CD4þ
T-effector cells react with specific antigens pre-
sented by MHCII molecules in association with a
proper expression of co-stimulatory molecules.
When T cells of ITP patients were stimulated by
platelet antigens, one could notice increased pro-
duction of both Th1 and Th2 cytokines. Th1 cells
produce IL-2, interferons, and tumor necrosis factor
(TNF), whereas Th2 cells produced IL-4, IL-13, and
IL-10, which are considered important in inhibiting
cell-mediated immune responses. The role of Th17
(known to be associated with many immune-
mediated diseases) in the pathogenesis of chronic
ITP was assessed. Higher levels of IL-17A and Th17-
related cytokines, and an increased percentage of IL-
17A producing CD4þ and neutrophils, were
observed in ITP patients.19–21 In addition, T-
effector cells are increasingly recruited into bone
marrow and other involved organs in ITP. To
determine the reason for this, expression of chemo-
kine receptors such as CX3CRI and CXCR4 was
analyzed in the bone marrow of ITP patients. Here,
T-cell surface expression of these chemokine recep-
tors was increased in patients compared with con-
trols. Furthermore, the number of CD3þ T cells in
bone marrow, but not in blood, along with increased
Fas expression was also found, emphasizing the
importance of cellular immunity in ITP22 (Figure 1).
Figure 1. Cellular mechanisms in ITP: the wide rage of
T-cell responses. Following a continuous presentation of
GPIIb/IIIa to T cells, Th1 overproduce TNF, IFNs, and IL-6
but also overexpress chemokine receptors such as CXCR4
and CXCR1. IL-17 and IL-4 are also overproduced by
TH17 and TH2 cells. Tregs are important in decreasing
the proliferation and activation of both TH1 and Th17 in
ITP. Finally, CTLs induce the destruction of mature
platelets by overexpressing Fas-ligand and overproducing
granzymes.
D. Yehudai et al.S102Cellular immune-mediated response in ITP is
frequently manifested by increased proliferation of
cytotoxic T cells. Many studies alluded to the
capability of cytotoxic T lymphocytes to alter mega-
karyocyte development and function, thereby con-
tributing to impaired platelet production. In this
respect, cell-mediated lysis of autologous platelets
in chronic ITP was observed using purified CD8þ T
cells as effector cells. These cells were shown to
overexpress Fas-ligand, mRNA levels of granzyme B,
perforin, and TNF-a. These results strengthen the
concept that apoptosis and perforin/granzyme-medi-
ated cytotoxicity constitute an important pathway
through which CTLs destroy autologous platelets23
(Figure 1).T-REGULATORY CELLS
The exact mechanisms of autoimmunity in medi-
ating ITP have not been investigated fully, but they
definitely include a clear imbalance between the
overactivity of effector T cells and the altered
function of Tregs. Recent advances in the field of
Tregs established their better molecular definition,
bringing new insights into their role in maintaining
self-tolerance.24,25 Therefore it was obvious to assess
the role of these cells in ITP. In patients with ITP,
naturally occurring CD4þCD25þ Tregs are both
functionally impaired and reduced in number. Aim-
ing to establish this finding, Tregs were measured in
44 patients with acute ITP. By using flow cytometry
analysis, the number of CD4þCD25þ T cells in
patients with ITP showed a very wide distributionin comparison to healthy individuals. The number of
Tregs was significantly lower in ITP patients in the
severe phase, and in patients positive for anti-GPIIb/
IIIa antibody. However, the number of those cells
increased in patients having full remission, especially
after splenectomy. In addition, Foxp3 mRNA levels
in peripheral blood mononuclear cells (PBMCs) of
ITP patients were higher when patients were in
remission than in those with refractory lower plate-
let counts.26 In another study, the production and
reduced immunosuppressive activity of Tregs in ITP
was investigated. The frequency of circulating
CD4þCD25þFoxp3þ Tregs in patients and controls
was comparable. However, sorted CD4þCD25high
cells from patients with chronic ITP (n ¼ 13) had
a twofold reduction of in vitro immunosuppressive
activity compared with controls (n ¼ 10, Po.05).
The impaired suppression was specific to Tregs, as
shown by cross-mixing experiments with T cells
from controls. These data suggest that functional
defects in Tregs are involved in the pathogenesis of
ITP.27 The above findings and others have led to the
understanding that the Treg count can possibly
correlate with the severity of ITP and, as such, might
be used as a tool for diagnosis and assessment of
improvement in ITP patients.28 In spite of their
pivotal role in maintaining peripheral immune toler-
ance, a very small and clinically ineffective number
of naturally Tregs (nTregs) can be found in periph-
eral blood. In their work, Zhang et al demonstrated
that platelet GP-specific induced Tregs (GP-iTregs)
could be generated de novo from non-regulatory
CD4þCD25CD45RAþ cells in patients with ITP,
and induced both antigen-specific and linked sup-
pression. They also showed that the Toll-like recep-
tor pathway is the dominant pathway (along with
notch and transforming growth factor-b pathways)
related to the GP-specific tolerance.29
Aiming to assess the beneficial effect of Tregs in
preventing ITP in mice, Treg-deficient mice were
studied by inoculation of Treg-depleted CD4þCD25
T cells isolated from BALB/c mice into syngeneic
nude mice intravenously. Platelet count, platelet-
associated anti-platelet antibodies, and IgG anti-
platelet antibody production in splenocyte cultures
were examined by flow cytometry. Of 69 Treg-
deficient mice, 25 (36%) spontaneously developed
thrombocytopenia that lasted at least 5 weeks. The
platelet-associated IgG level and proportion of reticu-
lated platelets were elevated in the thrombocyto-
penic mice. The transfer of Tregs efficiently
prevented the onset of thrombocytopenia, but Treg
transfer after the onset of thrombocytopenia had no
apparent effect. Treatment with IgG anti-cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) antibodies
canceled this Treg-governed suppressive effect.
These results indicate that Tregs are capable of
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cytopenia by engaging CTLA-430 (Figure 1).Figure 2. Humoral mechanisms in ITP: anti-platelet
antibodies: (A). GPIIb/IIIa are presented to Th1 effector
cells. These enhance the proliferation of autoreactive B
cells and the production of anti-GPIIb/IIIa antibodies.
(B) Autoreactive B cells are stimulated by increased levels
of BAFF. This is followed by a continuous production of
anti-platelet antibodies. (C) Anti-GPIIb/IIIa bind megakar-
yocytes and inhibit their maturation to normal platelets.B-CELL AUTOIMMUNITY IN ITP
Once tolerance for platelet antigens is lost, few
pathways can lead to ITP, including antibody-medi-
ated, complement-dependent, and apoptosis. Anti-
platelet autoantibodies can bind to platelets and
megakaryocytes, where it has been shown to not
only cause platelet destruction but also decrease
their production by interfering with megakaryocyte
maturation/proliferation or by causing intramedul-
lary platelet destruction.31
Autoantibody-mediated complement activation on
platelets is a common finding in ITP patients, and its
frequency and specificity have been studied. Najaoui
et al32 clearly showed that the major targets for
complement-fixing autoantibodies are GPIIb/IIIa and
GPIb/IX, and that in a significant number of patients
with chronic ITP, platelet autoantibodies are capable
of activating the classical complement pathway.
They reported on the presence of complement
fixation even in ITP sera with very low titers of
autoantibodies. One of the potential (of high clinical
significance) components of autoimmunity in ITP is
BAFF (B-cell activating factor of the TNF family), a
crucial cytokine for normal development and sur-
vival of B cells33 (Figure 2). In order to investigate
this issue, Zhou et al explored the crucial role for
BAFF in the pathogenesis of ITP, by measuring BAFF/
BAFF-R levels and evaluating the connection
between clinical parameters and expression levels.34
They found significantly higher serum BAFF levels in
untreated ITP patients compared to normal controls
and treated ITP patients. A weak correlation
between platelet counts and BAFF levels was
noticed. However, no statistical difference in BAFF
levels between acute and chronic ITP was found.
These results questioned BAFF being a marker for
ITP disease activity but clearly point to its role in ITP
development and autoimmunity.
Antiphospholipid antibodies (APLA) are fre-
quently found in serum of ITP patients. In their
work, Pierrot-Deseilligny et al35 found APLA [anti-
cardiolipin (aCL) and/or lupus anticoagulant (LA)]
in 26% of 215 ITP patients: anticardiolipin alone
in 18%, lupus anticoagulant in 0.5%, and the combi-
nation of both in 7%. Thrombotic events, character-
istic of anti-phospholipid syndrome (APS), were low
(7%), but were associated with age and high IgG-aCL
levels, suggesting a potential benefit in testing for
aPL when ITP is diagnosed. Bidot et al investigated
the prevalence of APLA in ITP and APS.36 They
observed few differences: (1) IgG and IgM antibodies
to b2GP1 were more common in APS than ITP,
while IgG antibodies against phospholipids (aCL,anti-phosphatidylcholine, anti-phosphatidylserine,
anti-phosphatidylethanolamine) were more common
in ITP than in APS (Po.05); (2) multiple APLA (Z3
antigens) were more frequent in APS than in ITP
(Po.05); (3) LA was frequently associated with APS
but was absent in ITP; (4) APLA is quite common in
ITP—two-thirds of subjects were positive for at least
one APLA. They concluded that the APLA profile
differs between ITP and APS. In APS, antibodies
were mainly against b2GP1 and 80% had positive
LA, while in ITP the APLA react mostly with the
phospholipids without LA. These differences might
explain the opposite clinical presentations in the
two diseases: thrombotic versus bleeding. Pratt et al
described the prevalence of antithyroid antibodies
(ATA) and antinuclear antibodies (ANA) in children
with ITP. Twenty-three percent of children with acute
ITP had acute non-platelet antibodies detected. In the
chronic ITP patients group, 33% had at least one
abnormal antibody value (ATA, ANA). Most of the
patients testing positive for autoantibodies were
female and/or 12 years of age or older. Their results
suggest patients with acute ITP who also have other
autoantibodies may be more likely to develop chronic
ITP than those lacking these autoantibodies.37THE DEVELOPMENT OF SLE IN ITP PATIENTS
The issue of ITP being primary or secondary to
SLE was the subject of many studies. When secon-
dary, ITP is usually mild to moderate, and the
D. Yehudai et al.S104treatment in this case is different, especially when
ITP is present in association with other hematologic
findings. Anti-platelet antibodies were reported to be
detected in 78% of SLE patients, often without
concurrent thrombocytopenia, and in up to 16% of
patients, isolated thrombocytopenia was their initial
clinical manifestation. The early recognition of
patients in whom isolated ITP is likely to progress
to SLE is crucial due to its both prognostic and
therapeutic importance.38–40
Several studies have attempted to identify clinical
or laboratory parameters that could possibly predict
which of the ITP patients are likely to develop SLE or
other autoimmune diseases. In this respect, Ander-
son and co-authors found that 24 of 117 adult
patients with ITP (20%) had a positive ANA titer.
Four of these patients developed later SLE; all of
them were women with high titers of ANA.41 In a
smaller study, six of 18 adult women with ITP (33%)
and positive ANA developed SLE within 4 years, all
with high ANA titer (Z1:160).42 In another study, 16
of 82 adult patients with chronic ITP (20%) had a
positive ANA recorded. Nine of these patients devel-
oped SLE within 6 months of ITP onset.43 These data
suggest that high titers of ANA in women with ITP
are a sensitive but nonspecific marker for predicting
the development of SLE. However, one should point
to other contrary experiences among children with
chronic ITP and ANA positivity who remained free of
any evidence of autoimmune diseases. With this
point of view, Kurata et al reported on 29 adult
patients with chronic ITP and positive ANA, but
none of whom developed SLE during a 3-year follow-
up period.44
In order to further clarify this issue, the clinical
significance of ANA positivity in children with
chronic ITP was further studied. To do so, a long-
term follow-up study of a large cohort was per-
formed to determine the likelihood that selected
children with ITP will develop signs and symptoms
of systemic autoimmune disease.45 Here, 147 chil-
dren with ITP were enrolled and divided by sex into
boys (n ¼ 77) and girls (n ¼ 70) and to those defined
as having acute (n ¼ 69) or chronic (n ¼ 78) ITP.
The average age of these patients was 7.0  4.8
years. ANA was assessed in only 87 of these patients,
typically at the time of diagnosis as a screening test
or due to an additional symptoms or a positive family
history. ANA was found to be positive (a median titer
of 1:160) in 25 of the 87 tested children. Correla-
tions between ANA results, family history of auto-
immune diseases, initial hemoglobin concentration,
initial platelet count, and/or the finding of elevated
platelet autoantibodies were not evident during a
short follow-up. However, when long-term follow-up
were examined, a higher incidence of autoimmune
symptoms was noted in the group of children withpositive ANAs. Of the 25 children with positive
ANAs, nine (36%) had further autoimmune symp-
toms during the follow-up period as compared to
none in the 62 children with negative ANAs
(Po.001). These were predominantly girls (n ¼ 8)
with a mean age of 12.2 years at diagnosis and most
of them had chronic ITP (n ¼ 7) rather than acute.
Autoimmune symptoms were more frequent in
those with ANA titersZ1:640 than those with lower
titers (67% v 31%), although this difference was not
statistically significant (P ¼ .20). Moreover, children
with a positive ANA together with other autoanti-
bodies, such as anti-dsDNA, were significantly more
likely to develop further autoimmune symptoms
(57% v 0%, P ¼ .04). The author’s conclusion was
that, similar to the experience noted by many in
adults, the presence of a positive ANA (especially of
high titers) together with the presence of other
autoantibodies, especially those to dsDNA, can be
helpful in identifying those patients with ITP who
are at increased risk of develop SLE. Several other
reports demonstrated later that female patients with
chronic ITP, high titers of ANA, and additional
autoantibodies (such as anti-dsDNA, cardiolipin,
anti-SSB-La/SSA-Ro) are candidates for developing
SLE in the future.46–48 Therefore, physicians have
to look for a combination of autoantibodies such as
anti-dsDNA, cardiolipin, and anti-Ro/La, specific
medical and familial history, and physical examina-
tion in order to better identify the minority of cases
in which the ITP heralds future SLE.NOVEL THERAPIES FOR ITP
The decision for treatment in patients with ITP
must take into account several factors, including the
age of the patient, the severity of the illness, and the
anticipated natural history. Adult patients, particu-
larly those older than 60 years of age, have a higher
incidence of major or fatal bleeding than children.49
However, therapy may not be necessary unless the
platelet count iso20  109/L or when extensive
bleeding develops. This review focuses on recent
advances in ITP treatment and not on traditional
approaches. The main goal of second-line therapy is
to attain a continual increase of the platelet count,
which is considered hemostatic for the patient. The
following treatment modalities have quite different
mechanisms of action, but they are intended to
induce long-term remission.Rituximab-Specific Anti-CD20 Antibody
Rituximab was found to be highly useful in ITP
patients, where 60% of them are usually considered
responders, with 40% achieving complete response.
Responses generally occur between 2–8 weeks of
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ers to 5 years or longer in 15%–20% of initially treated
patients. Initial complete response and prolonged B-
cell depletion are considered useful predictors for
sustained responses.50–52 In a prospective study,
following one treatment of rituximab, 33% of
patients had a platelet count of 50  109/L or higher
and 40% had a platelet count of 30  109/L or higher.
In this respect, most patients with a durable (41
year) complete response will respond to a repeated
treatment when they relapse. In the above studies,
rituximab was used in doses of 375 mg/m2, but lower
doses (100 mg administered intravenously weekly for
4 weeks) also may be effective, although associated
with a longer time to response.53,54 Further studies
are warranted to identify the optimal dose and the
best treatment protocol. Recently it has been
reported that high response rates were shown for a
combination of rituximab with high-dose dexametha-
sone as initial therapy. At this stage, one should
question whether rituximab could be a better treat-
ment choice than splenectomy in order to achieve
remission as a second-line therapy. Although having
fewer side effects, there are not enough current data
to support the replacement of splenectomy with
rituximab as a second-line treatment for chronic
ITP.55
The main mechanisms by which rituximab is
beneficial in patients with ITP is by eliminating
normal B cells, but also those producing anti-
platelet antibodies. This B-cell depletion is almost
always transient and has few side effects or toxicities.
Rituximab was shown also to exert significant effects
on cellular immunity. Pretreatment abnormalities of
T cells in ITP patients were reverted in responders of
rituximab as opposed to non-responders, where they
remained unchanged. By being immunomodulatory,
rituximab produces clinical remission in ITP when
expansion of pathogenic T cells is still dependent on
B-cell costimulation. However, when ITP is advanced
and T-lymphocyte clones are more expanded, they
continue to drive B-cell activity and antibody produc-
tion, irrespective of the cytokine microenvironment
produced in turn by these B cells. A large clinical trial
supported the notion that at this stage of ITP
rituximab is ineffective. In this study, patients with
a short duration of disease, in whom presumably T-
cell expansion was B-cell–dependent, were much
more likely to respond to treatment than those with
longer ITP duration. Therefore, non-responsiveness
to anti-CD20 therapy in ITP may be related to an
inability to modify the oligoclonal nature of the T-cell
subsets.56,57
Adverse effects of rituximab are usually mild or
moderate, with a low incidence of infections. There
are also reports of several cases with progressive
multifocal leukoencephalopathy associated withrituximab treatment in patients with lymphoma and
and patients with SLE and ITP, who were heavily
immunosuppressed and on combination treatments.
Thus, additional long-term safety data are required.58,59Thrombopoietin-Receptor Agonists:
Romiplostim and Eltrombopag
Until now, all known treatments for ITP were
generated in order to suppress the production of
autoantibodies and/or inhibiting macrophage-
mediated destruction of opsonized platelets. How-
ever, some ITP patients have impaired platelet
production rather than increased platelet destruc-
tion. Additionally, ITP patients have normal or
slightly elevated thrombopoietin (TPO; the main
regulator of platelet production) levels. These levels
are lower than the serum levels found in patients
with megakaryocytic hypoplasia, probably as a result
of active TPO uptake and destruction by the
expanded megakaryocyte mass in ITP. With this in
mind, the uses of TPO for stimulation of megakar-
yopoiesis and the increase of platelet count in ITP
were suggested.60 The first-generation of TPO used
in clinical trials included recombinant human TPO
(rhTPO), and a non-glycosylated, truncated form of
TPO coupled to polyethylene glycol. The recombi-
nant protein, called ‘‘megakaryocyte growth and
differentiation factor’’ (MGDF), had structural and
immunogenic differences compared to native TPO,
due to which immunogenic adverse effects were
noticed.61 Clinical trials were discontinued after the
development of TPO autoantibodies was demon-
strated in healthy volunteers and did not yield a
clinically therapeutic advantage.61,62 Recently, how-
ever, intense research and development has been
focused on second-generation thrombopoietic
growth factors. These new molecules have no
structural resemblance to TPO, but still bind and
activate the TPO receptor, and were hence given the
name of ‘‘TPO-receptor agonists.’’ Studies have been
completed and the US Food and Drug Administration
approved two TPO mimetics, romiplostim and
eltrombopag. Romiplostim is administered as a 1–
10 mg/kg subcutaneous weekly injection. Eltrombo-
pag is an oral non-peptide TPO-receptor agonist
administered as a 25, 50, or 75 mg daily dose. Data
from clinical trials have demonstrated that both
drugs are highly effective in increasing the platelet
count in both healthy volunteers and ITP patients.
In two placebo-controlled, double-blind randomized
trials, romiplostim was given to splenectomized and
non-splenectomized ITP patients for 6 months. An
overall platelet response rate (44 weeks out of 24
study weeks450  109/L) was observed in 79% and
88% of romiplostim-treated patients, compared with
0% and 14% in the respective placebo treatment
D. Yehudai et al.S106group. In these romiplostim studies, it was demon-
strated that 87% of romiplostim-treated patients had
reduced or discontinued other modalities of ITP
therapy, including corticosteroids and intravenous
immunoglobulin. Long-term follow-up of patients
treated with romiplostim showed that responses
were sustained for 4 years on continuous therapy
and that most ITP patients were able to decrease or
even discontinue concurrent corticosteroid ther-
apy.62,63 This is an important therapy result, since
many of these patients are on immunosuppressive
treatment for a long period of time.
Similar results have been demonstrated with
eltrombopag in chronic relapsed or refractory ITP
patients. Although most adverse effects were mild,
the main concern of these therapies is the increased
bone reticulin, which was found in 10 of 271
patients included in the romiplostim trials and in
seven of 117 patients in the eltrombopag trials (o6%
overall). Further studies are warranted in order to
determine the importance of this finding. Another
side effect was liver function test abnormalities,
which were seen in 13% of eltrombopag-treated
patients.63–65 Due to their mechanism of action,
these TPO-receptor agonists are considered as a
maintenance therapy. Upon cessation of treatment,
most patients return to lower platelet counts (410%
transiently falling below baseline platelet counts);
however, few patients are able to discontinue treat-
ment successfully.CONCLUSION
Both humoral and cellular mechanisms are
involved in the development of ITP. The role of
Tregs is of special pathogenic importance and could
be applied in future therapeutic approaches.
Patients in whom ANA, aPL, and anti-dsDNA anti-
bodies exist are candidates to develop SLE and or
APS. New novel therapeutic approaches are already
in practice for refractory ITP patients.
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